|Description||Burosumab is a human monoclonal antibody targeting the phosphaturic hormone fibroblast growth factor 23 (FGF23). Burosumab is currently in a phase III clinical trial for the treatment of patients with X-linked hypophosphatemia.|
|Brife Description||human monoclonal antibody|
|Synonyms||KRN-23; KRN 23; KRN23|
|Application||the potential treatment of X-linked hypophosphatemia|
|Current Developer||Ultragenyx Pharmaceutical; Kyowa Hakko Kirin|
Corydaline, extracted from Corydalis ambigua, is one of the major active constituents in a new prokinetic botanical agent exhibiting the antiacetylcholinesteras...
A metabolite of acetaminophen, which is is a pain reliever and a fever reducer.
Talsupram hydrochloride is a selective noradrenalin reuptake (SLC6A2) inhibitor, displaying high affinity for the human noradrenalin transporter (NET) against S...
PKR-IN-2 is a pyruvate kinase (PKR) activator. IC50: PKR (R510Q) ＜100 nM
Choline chloride is a quaternary ammonium salt used as an additive for animal feed, especially for chickens where it accelerates growth.
Nobiletin, a citrus flavonoid isolated from citrus peels like in tangerine, which has anti-inflammatory and anti-tumor activities.
LY 140091 is a bio-active chemical, but no detailed information has been published yet.
BI-44847 is a synthetic bio-active chemical had been in phase II clinical trials for the treatment of type 2 diabetes.